Slingshot members are tracking this event:

ZIOPHARM (ZIOP) to finish Phase 1 study of Ad-RTS-hIL-12 with Veledimex in Subjects With Glioblastoma or Malignant Glioma in December 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details In November 2015, the Company reported biologic data from the multicenter, Phase 1 gene therapy study of GBM at the Society for Neuro-Oncology (SNO) 20th Annual Scientific Meeting. Following reporting of encouraging data from the first cohort of the study at the initial dosing of Ad-RTS-IL-12 + veledimex, the Company announced this week that the first patient has been enrolled in the study's second dose cohort. The Company plans to report updated results from the study at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 17, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Study, Ad-rts-hil-12, Veledimex, Glioblastoma, Glioma, Open-label, Brain Cancer